Lexeo Therapeutics, Inc. Common Stock Financial Flexibility Index
Lexeo Therapeutics, Inc. Common Stock financial flexibility index. Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Financial Flexibility Index of -0.89x as of June 2026. Free cash flow of $-17.59 Million (operating CF $-17.60 Million minus capex $7.00K) represents -1% of total liabilities ($19.84 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Lexeo Therapeutics, Inc. Common Stock (2020–2025)
Financial flexibility index of Lexeo Therapeutics, Inc. Common Stock from 2020 to 2025. Historical Financial Flexibility Index trend for Lexeo Therapeutics, Inc. Common Stock across 6 annual periods. Explore how well can Lexeo Therapeutics, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Lexeo Therapeutics, Inc. Common Stock Financial Flexibility Index by Year (2020–2025)
Lexeo Therapeutics, Inc. Common Stock financial flexibility index by year from 2020 to 2025. Year-by-year free cash flow to debt coverage for Lexeo Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Lexeo Therapeutics, Inc. Common Stock (LXEO) cash conversion ratio.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -4.46x | $-98.16 Million | $-98.56 Million | $22.02 Million | ▼ -66.3% |
| 2024 | -2.68x | $-80.67 Million | $-81.15 Million | $30.10 Million | ▼ -18.7% |
| 2023 | -2.26x | $-59.33 Million | $-59.50 Million | $26.27 Million | ▼ -783.9% |
| 2022 | -0.26x | $-53.66 Million | $-54.56 Million | $210.03 Million | ▼ -11.8% |
| 2021 | -0.23x | $-43.99 Million | $-44.18 Million | $192.46 Million | ▼ -154.9% |
| 2020 | -0.09x | $-3.13 Million | $-3.13 Million | $34.95 Million | — |